Pentoxifylline as an adjunctive in treatment of negative symptoms in chronic schizophrenia: A double‐blind, randomized, placebo‐controlled trial

AIM: The aim of this study was to explore the effectiveness and safety of pentoxifylline as an adjuvant to risperidone in mitigating the negative symptoms in patients with chronic schizophrenia. METHODS: In this randomized, placebo‐controlled study, eighty outpatients with chronic schizophrenia were...

Descripción completa

Detalles Bibliográficos
Autores principales: Abdallah, Mahmoud S., Mosalam, Esraa M., Hassan, Ahmed, Ramadan, Ahmed N., Omara‐Reda, Hend, Zidan, Abdel‐Aziz A., Samman, Waad A., El‐berri, Eman I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9804082/
https://www.ncbi.nlm.nih.gov/pubmed/36341700
http://dx.doi.org/10.1111/cns.14010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9804082/
https://www.ncbi.nlm.nih.gov/pubmed/36341700
http://dx.doi.org/10.1111/cns.14010

Ejemplares similares